Top

Published in:

01-12-2007 | Case Report

Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients

Authors: Senol Kobak, Fahrettin Oksel, Yasemin Kabasakal, Eker Doganavsargil

Published in: Clinical Rheumatology | Issue 12/2007

Abstract

Secondary (AA) amyloidosis is one of the most significant complications of ankylosing spondylitis (AS) that frequently leads to proteinuria and renal dysfunction. Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis. We report three cases with AS-related AA amyloidosis that responded well to etanercept therapy. Despite treatment with disease modifying anti-rheumatic drugs, all three patients had active AS, marked proteinuria, impaired renal function, and low serum albumin level. During 1-year treatment with etanercept, all patients experienced gradual improvement in all of these parameters.

Husby G (1992) Amyloidosis. Semin Arthritis Rheum 22:67–82CrossRefPubMed

Buxbaum J (1998) The amyloidoses. In: Klippel JH, Dieppe PA (eds) Rheumatology, 2nd edn. Mosby, St. Louis, pp 5.24.7–10

Mladenovic J, Geisic L, Kerimovic D, Aramasic M, Merovic Z (1975) Incidence of amyloidosis in rheumatoid arthritis and ankylosing spondylitis. Scand J Rheumatol 4(Suppl 8):39

Hazenberg BP, van Rijswijk MH (1994) Clinical and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 8:661–690CrossRefPubMed

Hawkins PN (1997) Diagnosis and treatment of amyloidosis. Ann Rheum Dis 56:631–633CrossRefPubMedPubMedCentral

Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A, a major acute phase protein, in normal and disease states. Curr Opin Hematol 7:64–69CrossRefPubMed

Yan SD, Zhu H, Zhu A et al (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643–651CrossRefPubMed

Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κb and by 17β-estradiol through Sp-1in human vascular endothelial cells. J Biol Chem 33:25781–25790CrossRef

Shibasaki T, Matsumoto H, Watabe K et al (1997) A case of renal amyloidosis associated with hepatic adenoma: the pathogenetic role of tumour necrosis factor-alpha. Nephron 75:350–353CrossRefPubMed

10.

Cunnane G, Whitehead AS (1999) Amyloid precursors and amyloidosis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 13:615–628CrossRefPubMed

11.

Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, Garcia-Vicuna R, Gonzalez-Mari MV, Laffon A, Garcia-Vicuna R (2005) Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118:552–556CrossRefPubMed

12.

Gottenberg JE, Merle-Vincent F, Bentaberry F et al (2003) Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 48:2019–2024CrossRefPubMed

13.

Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome (letter). N Engl J Med 343:1044–1045CrossRefPubMed

14.

Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002) Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571–2573CrossRefPubMed

Title: Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients
Authors: Senol Kobak
Fahrettin Oksel
Yasemin Kabasakal
Eker Doganavsargil
Publication date: 01-12-2007
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 12/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-007-0679-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2007

Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus

The Fibromyalgia Bladder Index

Colchicine-induced rhabdomyolysis

Churg-Strauss syndrome triggered by hyposensitization to Alternaria fungus

Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?

Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials